The Effect of Low-Dose Carvedilol, Nebivolol, and Metoprolol on Central Arterial Pressure and Its Determinants: A Randomized Clinical Trial

Journal of Clinical Hypertension

Volumn 15, Issue 12, 2013, Pages 910-917

  Studinger, Péter ^a   Tabák, Ádám G ^a,b   Chen, Chen Huan ^c,d   Salvi, Paolo ^e   Othmane, Taha E H ^a   Torzsa, Péter ^a   Kapocsi, Judit ^a   Fekete, Bertalan C ^a   Tislér, András ^a  

^a SEMMELWEIS UNIVERSITY OF MEDICINE   (Hungary)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

^c NATIONAL YANG MING UNIVERSITY   (Taiwan)

^d TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

^e ISTITUTO AUXOLOGICO ITALIANO   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; CALCIUM; CARVEDILOL; CHOLESTEROL; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METOPROLOL SUCCINATE; NEBIVOLOL; POTASSIUM; TRIACYLGLYCEROL; URIC ACID;

ADULT; AGED; ALBUMIN BLOOD LEVEL; ARTERIAL PRESSURE; ARTICLE; AUGMENTATION INDEX; CALCIUM BLOOD LEVEL; CHOLESTEROL BLOOD LEVEL; COLD SENSATION; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DIZZINESS; DRUG EFFECT; DRUG WITHDRAWAL; ERECTILE DYSFUNCTION; FEMALE; FOLLOW UP; GLUCOSE BLOOD LEVEL; HEART RATE; HUMAN; HYPERTENSION; HYPOTENSION; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; OPEN STUDY; PARALLEL DESIGN; POTASSIUM BLOOD LEVEL; PRIORITY JOURNAL; PROSPECTIVE STUDY; PULSE PRESSURE; PULSE WAVE; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SKIN TOXICITY; SYSTOLIC BLOOD PRESSURE; TONOMETRY; TREATMENT OUTCOME; TRIACYLGLYCEROL BLOOD LEVEL; URIC ACID BLOOD LEVEL; VASODILATATION;

ADOLESCENT; ADRENERGIC BETA-1 RECEPTOR ANTAGONISTS; ADULT; AGED; ARTERIAL PRESSURE; BENZOPYRANS; CARBAZOLES; ETHANOLAMINES; FEMALE; HEART RATE; HUMANS; HYPERTENSION; MALE; MANOMETRY; METOPROLOL; MIDDLE AGED; PROPANOLAMINES; PROSPECTIVE STUDIES; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84888876860     PISSN: 15246175     EISSN: 17517176     Source Type: Journal    
DOI: 10.1111/jch.12210     Document Type: Article

References (25)

1. Wilkinson IB, MacCallum H, Flint L, et al. The influence of heart rate on augmentation index and central arterial pressure in humans. J Physiol. 2000;525:263-270.
2. Morgan T, Lauri J, Bertram D, Anderson A. Effect of different antihypertensive drug classes on central aortic pressure. Am J Hypertens. 2004;7:118-123.
3. Mackenzie IS, McEniery CM, Dhakam Z, et al. Comparison of the effects of antihypertensive agents on central blood pressure and arterial stiffness in isolated systolic hypertension. Hypertension. 2009;54:409-413.
4. London GM, Asmar RG, O'Rourke MF, Safar ME. Reason Project Investigators. Mechanism(s) of selective systolic blood pressure reduction after a low-dose combination of perindopril/indapamide in hypertensive subjects: comparison with atenolol. J Am Coll Cardiol. 2004;43:92-99.
5. Williams B, Lacy PS, Thom SM, et al. CAFE Investigators; Anglo-Scandinavian Cardiac Outcomes Trial Investigators; CAFE Steering Committee and Writing Committee. Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes: principal results of the Conduit Artery Function Evaluation (CAFE) study. Circulation. 2006;113:1213-1225.
6. Agabiti-Rosei E, Porteri E, Rizzoni D. Arterial stiffness, hypertension, and rational use of nebivolol. Vasc Health Risk Manag. 2009;5:353-360.
7. Dhakam Z, Yasmin, McEniery CM, et al. A comparison of atenolol and nebivolol in isolated systolic hypertension. J Hypertens. 2008;26:351-356.
8. Mahmud A, Feely J. Β-blockers reduce aortic stiffness in hypertension but nebivolol, not atenolol, reduces wave reflection. Am J Hypertens. 2008;21:663-667.
9. Kampus P, Serg M, Kals J, et al. Differential effects of nebivolol and metoprolol on central aortic pressure and left ventricular wall thickness. Hypertension. 2011;57:1122-1128.
10. Jabbour A, Macdonald PS, Keogh AM, et al. Differences between β-blockers in patients with chronic heart failure and chronic obstructive pulmonary disease: a randomized crossover trial. J Am Coll Cardiol. 2010;55:1780-1787.
11. Shah NK, Smith SM, Nichols WW, et al. Carvedilol reduces aortic wave reflection and improves left ventricular/vascular coupling: a comparison with atenolol (CENTRAL Study). J Clin Hypertens (Greenwich). 2011;13:917-924.
12. Barna I, Keszei A, Dunai A. Evaluation of Meditech ABPM-04 ambulatory blood pressure measuring device according to the British Hypertension Society protocol. Blood Press Monit. 1998;3:363-368.
13. Salvi P, Lio G, Labat C, et al. Validation of a new non-invasive portable tonometer for determining arterial pressure wave and pulse wave velocity: the PulsePen device. J Hypertens. 2004;22:2285-2293.
14. El AM, Topouchian J, Asmar R. Evaluation of two devices for self-measurement of blood pressure according to the international protocol: the Omron M5-I and the Omron 705IT. Blood Press Monit. 2003;8:127-133.
15. Laurent S, Cockcroft J, Van BL, et al. European Network for Non-invasive Investigation of Large Arteries: expert consensus document on arterial stiffness: methodological issues and clinical applications. Eur Heart J. 2006;27:2588-2605.
16. Takazawa K, Tanaka N, Takeda K, et al. Underestimation of vasodilator effects of nitroglycerin by upper limb blood pressure. Hypertension. 1995;26:520-523.
17. Murgo JP, Westerhof N, Giolma JP, Altobelli SA. Aortic input impedance in normal man: relationship to pressure wave forms. Circulation. 1980;62:105-116.
18. Westerhof BE, Guelen I, Westerhof N, et al. Quantification of wave reflection in the human aorta from pressure alone: a proof of principle. Hypertension. 2006;48:595-601.
19. Liao CF, Cheng HM, Sung SH, et al. Determinants of pressure wave reflection: characterization by the transit time-independent reflected wave amplitude. J Hum Hypertens. 2011;25:665-671.
20. Davis JT, Pasha DN, Khandrika S, et al. Central hemodynamics in prehypertension: effect of the β-adrenergic antagonist nebivolol. J Clin Hypertens (Greenwich). 2013;15:69-74.
21. Tham TC, Guy S, McDermott BJ, et al. The dose dependency of the alpha- and β-adrenoceptor antagonist activity of carvedilol in man. Br J Clin Pharmacol. 1995;40:19-23.
22. Goldberger JJ. Sympathovagal balance: how should we measure it? Am J Physiol. 1999;276:H1273-H1280.
23. Zepeda RJ, Castillo R, Rodrigo R, et al. Effect of carvedilol and nebivolol on oxidative stress-related parameters and endothelial function in patients with essential hypertension. Basic Clin Pharmacol Toxicol. 2012;111:309-316.
24. Xiaozhen H, Yun Z, Mei Z, Yu S. Effect of carvedilol on coronary flow reserve in patients with hypertensive left-ventricular hypertrophy. Blood Press. 2010;19:40-47.
25. Nishiyama K, Tsutamoto T, Yamaji M, et al. Dose-dependent prognostic effect of carvedilol in patients with chronic heart failure-special reference to transcardiac gradient of norepinephrine. Circ J. 2009;73:2270-2275.